Goal setting and attainment in Alzheimer's disease patients treated with donepezil

Journal of Neurology Neurosurgery and Psychiatry

Volumn 73, Issue 5, 2002, Pages 500-507

  Rockwood, K ^a   Graham, J E ^a   Fay, S ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DONEPEZIL;

ADULT; AGED; ALZHEIMER DISEASE; ANXIETY DISORDER; ARTICLE; BEHAVIOR; CAREGIVER; CLINICAL TRIAL; COGNITION; CONFUSION; DEPRESSION; DIARRHEA; DYSPEPSIA; FEMALE; FLU LIKE SYNDROME; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PAIN; PATIENT ATTITUDE; PHASE 4 CLINICAL TRIAL; PHYSICIAN ATTITUDE; PRIORITY JOURNAL; PSYCHOMETRY; SOCIAL INTERACTION; TRANSIENT ISCHEMIC ATTACK; VERTIGO; WEIGHT REDUCTION;

EID: 0036828777     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.73.5.500     Document Type: Article

References (44)

1. Davis KL, Mohs RC, Marin D, et al. Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA 1999;21:1401-6.
2. Francis PT, Palmer AM, Snape M, et al. The cholinergic hypothesis of Alzheimer's disease: A review of progress. J Neuro Neurosurg Psychiatry 1999;66:137-47.
3. Mayeux R, Sao M. Treatment of Alzheimer's disease. N Engl J Med 1999;341:1670-9.
4. Pryse Phillips W. Do we have drugs for dementia? No. Arch Neurol 1999;56:735-7.
5. Birks JS, Melzer D, Beppu H. Donepezil for mild and moderate Alzheimer's disease (Cochrane Review). In: The Cochrane Library, Issue 1, 2001. Oxford: Update Sofware.
6. Olin J, Schneider L. Galantamine for Alzheimer's disease (Cochrane Review). In: The Cochrane Library, Issue 1, 2001. Oxford: Update Software.
7. Birks J, Grimley Evans J, Iakovidou V, et al. Rivastigmine for Alzheimer's disease (Cochrane Review). In: The Cochrane Library, Issue 2, 2001. Oxford: Update Software.
8. Greenberg SM, Tennis MK, Brown LB, et al. Donepezil therapy in clinical practice. Arch Neurol 2000;57:94-9.
9. Rockwood K, MacKnight C. Assessing the clinical importance of statistically significant improvement in anti dementia drug trials. Neuroepidemiology 2001;20:51-6.
10. Swanwick GRJ, Lawlor BA. Initiating and monitoring cholinesterase inhibitor treatment for Alzheimer's disease. Int J Geriat Psychiatry 1999;14:244-8.
11. Joffres C, Graham J, Rockwood K. Qualitative analyses of the clinicians' interview-based impression of change (plus): Methodological issues and implications for clinical research. International Psychogeriatrics 2000;12:403-13.
12. Winblad B, Brodaty H, Gauthier S, et al. Pharmacotherapy of Alzheimer's disease: Is there a need to redefine treatment success? Int J Geriatr Psychiatry 2001;16:653-66.
13. Spilker B. Guide to Clinical Trials. New York, NY: Raven Press, 1991.
14. Rockwood K, Stolee P, Howard K, Mallery L. Use of goal attainment scaling to measure treatment effects in an anti-dementia drug trial. Neuroepidemiology 1996;15:330-3.
15. Bogardus ST Jr, Bradley EH, Tinetti ME. A taxonomy for goal setting in the care of persons with dementia. J Gen Intern Med 1998;13:675-80.
16. Hartman D, Borrie MJ, Davison E, et al. Use of goal attainment scaling in a dementia special care unit. Am J Alz Dis 1997;12:111-16.
17. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-44.
18. Clarfield AM. Canadian Consensus Conference on the Assessment of Dementia. Can Med Assoc J 1991;144 (suppl).
19. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-64.
20. Kraemer HC, Thieman S. How Many Subjects? Statistical Power Analysis in Research. Newbury Park: Sage, 1987.
21. Kiresuk TJ, Sherman RE. Goal Attainment Scaling: A general method for evaluating comprehensive community mental health programs. Community Ment Health J 1968;4:443-53.
22. Stolee P, Rockwood K, Fox RA, et al. The use of goal attainment scaling in a geriatric care setting. J Am Geriatr Soc 1992;40:574-8
23. Joyce B, Rockwood K, Mate-Kole C. Use of Goal Attainment Scaling in brain injury in a rehabilitation hospital. Am J Phys Med Rehabil 1994;37:10-14.
24. Gordon J, Powell C, Rockwood K. Goal Attainment Scaling as a measure to assess clinically important change in the nursing home. Age Ageing 1999;28:275-81.
25. Rockwood K, Stolee P, Fox RA. The Use of Goal Attainment Scaling in measuring clinically important change in the frail elderly. J Clin Epidemiol 1993;46:1113-18.
26. Rockwood K, Joyce B, Stolee P. Use of Goal Attainment Scaling in measuring clinically important change in rehabilitation patients with traumatic brain injury. J Clin Epidemiol 1997;50:581-8.
27. Rockwood K, Stadnyk K, Carver D, et al. A clinimetric evaluation of specialized geriatric care for frail elderly people. J Am Geriatr Soc 2000;48:1080-5.
28. Kiresuk, TJ, Smith RE, Cardillo JE. Goal Attainment Scaling: Applications Theory and Measurement. Hillside, NJ: Lawrence Erlbaum Associates, 1994.
29. Folstein MF, Folstein SE, McHugh PR. Mini-mental-state: A practical method for grading the cognitive state of patients for the clinician. J Psychiatric Res 1975;12:189-98.
30. Standish T, Molloy DW, Bedard M, et al. Improved reliability of the Standardized Alzheimer's Disease Assessment Scale (SADAS) compared with the Alzheimer's Disease Assessment Scale (ADAS). J Am Geriatr Soc 1996;44:712-16.
31. Lawton MP, Brody EM. Assessment of older people: Self-maintaining and instrumental activities of daily living. Gerontologist 1969;9:179-86.
32. Pfeffer RI, Kurosaki TT, Harrah CH, et al. Measurement of functional activities in older adults in the community. J Gerontol 1982;37:323-9.
33. Pfeffer RI, Kurosaki TT, Chance JM, et al. Use of the mental function index in older adults: Reliability, validity and measurement of change over time. Am J Epidemiol 1984;120:922-35.
34. Abrams A, Young S. Cornell scale for depression in dementia. Biol Psychiatry 1988;23:271-84.
35. Lyness JM, Kelly Noel T, Cox C, et al. Screening for depression in elderly primary care patients. Arch Intern Med 1997;157:449-54.
36. Radloff, LS. The CES-D scale: A self-report depression scale for research in the general population. Applied Psychological Measurement 1977;1:385-401.
37. Knopman DS, Knapp MJ, Gracon IS, et al. The Clinician Interview-Based Impression (CIBI): A clinician's global change rating scale in Alzheimer's disease. Neurology 1994;44:2315-21.
38. Graham JE. Diagnosing Dementia: Signs, Symptoms and Meaning. [Doctoral dissertation]. Quebec: University of Montreal, 1996. National Archives of Canada.
39. Rogers SL, Friedhoff LT, the Donepezil Study Group. The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia 1996;7:293-303.
40. Rogers SL, Farlow MR, Doody RS, et al. A 24-week double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998;50:136-45.
41. Burns A, Rossor M, Hecker J, et al. The effects of donepezil in Alzheimer's disease - Results from a multinational trial. Dement Geriatr Cogn Disord 1999;10:237-44.
42. Winblad B, Engedal K, Soininen H, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001;57:489-95.
43. Mohs RC, Doody RS, Morris JC, et al. A 1-year placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001;54:481-8.
44. Mitnitski, AB, Graham JE, Mogilner AJ, et al. The rate of decline of functions in Alzheimer's disease and other dementias. J Gerontol Med Sci 1999;54A:M65-9.